<DOC>
	<DOCNO>NCT00750620</DOCNO>
	<brief_summary>The objective study ass compare pharmacokinetic property YM178 normal subject mild , moderate severe renal impairment .</brief_summary>
	<brief_title>A Pharmacokinetic Study YM178 Normal Subjects Those With Mild , Moderate , Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>good health renal impairment body mass index ( BMI ) 18 40 kg/m2 subject renal impairment stable dose concomitant medication least 2 week subject liver enzyme abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>mild , moderate , severe renal impaired subject</keyword>
	<keyword>normal renal function subject</keyword>
	<keyword>Glomerular filtration rate ( GFR )</keyword>
	<keyword>Modification Diet Renal Disease ( MDRD ) formula</keyword>
	<keyword>YM178</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>